title: FDA "black box" labeling.
authors.affiliation: Office of Drug Evaluation II, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA. meyerro@cder.fda.gov
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Meyer
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000932:Antiemetics / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D004329:Droperidol / Q000009:adverse effects*; D004348:Drug Labeling; D019317:Evidence-Based Medicine; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000932:Antiemetics; D014150:Antipsychotic Agents; D004329:Droperidol